Meta-Analysis: A Comparison of Aspirin and Rivaroxaban for Prophylaxis of Venous Thromboembolism After Hip or Knee Arthroplasty.

Abstract

Purpose: Knee arthroplasty and hip arthroplasty (THA) patients are susceptible to post-operative venous thromboembolism(VTE). Doctors are increasingly recommending the application of different thromboprophylaxis agents such as rivaroxaban. The agents are primarily effective in preventing thromboembolism after hip and knee arthroplasty. Similarly, recent research suggests aspirin as one of the cost-effective interventions for preventing thromboembolism. Accordingly, this meta-analysis aims to compare the effectiveness of Aspirin against Rivaroxaban for the prevention or treatment of thromboembolism following knee arthroplasty and knee arthroplasty.Methods: The researcher relied on electronic searches of about five databases. The database searches identified relevant studies used to extract meta-analyzed data and information. The databases included PubMed, Cinahl, Medicine, Cochrane Database of Systematic Reviews(CDSR), Pharma GKB, SAGE, from inception to December 2020.Results: Different studies from the five databases we are included in this study. The studies include 2257 in the aspirin group and 2337 in the rivaroxaban group. The result revealed no significant difference between Aspirin and Rivaroxaban for the treatment of venous thromboembolism.Conclusion: The meta-analysis result affirmed no statistically significant difference between Aspirin and Rivaroxaban in preventing venous thromboembolism, a joint arthroplasty, or hip fracture surgery. However, some health care professionals find aspirin a more effective, safe, convenient, and affordable alternative for preventing venous thromboembolism. Thus the meta-analysis recommends extensive randomized studies to confirm the stipulated outcomes.